Screening and analysis of key active constituents in Guanxinshutong capsule using mass spectrum and integrative network pharmacology.
10.1016/S1875-5364(18)30060-8
- Author:
Feng LIU
1
,
2
,
3
;
Xia DU
4
;
Pei-Rong LIU
5
;
Yu-Hong SUN
6
;
Yan-Min ZHANG
7
Author Information
1. School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China
2. Shaanxi Institute of International Trade & Commence, Xianyang 712046, China
3. Shaanxi Buchang Pharmaceutical Co. Ltd, Xi'an 710075, China.
4. Shannxi Academy of Traditionnal Chinese Medicine, Xi'an 710003, China.
5. School of Life Sciences, Northwest University, Xi'an 710069, China.
6. Shaanxi Institute of International Trade & Commence, Xianyang 712046, China.
7. School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China. Electronic address: zhang2008@mail.xjtu.edu.cn.
- Publication Type:Journal Article
- Keywords:
Calcium signaling pathway;
Cardiovascular diseases;
Guanxinshutong capsule;
Mass spectrum;
Systems pharmacology
- MeSH:
Animals;
Animals, Newborn;
Camphanes;
chemistry;
Cardiotonic Agents;
chemistry;
pharmacology;
Cells, Cultured;
Drugs, Chinese Herbal;
chemistry;
pharmacology;
Eugenol;
chemistry;
Gene Expression;
drug effects;
Hydroxybenzoates;
chemistry;
Mass Spectrometry;
Models, Biological;
Myocytes, Cardiac;
drug effects;
Nitric Oxide Synthase Type III;
genetics;
Phenanthrenes;
chemistry;
Rats;
Rats, Sprague-Dawley;
Receptor, PAR-1;
genetics;
Systems Biology
- From:
Chinese Journal of Natural Medicines (English Ed.)
2018;16(4):302-312
- CountryChina
- Language:English
-
Abstract:
Guanxinshutong capsule (GXSTC) is an effective and safe traditional Chinese medicine used in the treatment of cardiovascular diseases (CVDs) for many years. However, the targets of this herbal formula and the underlying molecular mechanisms of action involved in the treatment of CVDs are still unclear. In the present study, we used a systems pharmacology approach to identify the active ingredients of GXSTC and their corresponding targets in the calcium signaling pathway with respect to the treatment of CVDs. This method integrated chromatographic techniques, prediction of absorption, distribution, metabolism, and excretion, analysis using Kyoto Encyclopedia of Genes and Genomes, network construction, and pharmacological experiments. 12 active compounds and 33 targets were found to have a role in the treatment of CVDs, and four main active ingredients, including protocatechuic acid, cryptotanshinone, eugenol, and borneol were selected to verify the effect of (GXSTC) on calcium signaling system in cardiomyocyte injury induced by hypoxia and reoxygenation. The results from the present study revealed the active components and targets of GXSTC in the treatment of CVDs, providing a new perspective to enhance the understanding of the role of the calcium signaling pathway in the therapeutic effect of GXSTC.
